Class prediction models of thrombocytosis using genetic biomarkers

Blood

Volumn 115, Issue 1, 2010, Pages 7-14

  Gnatenko, Dmitri V ^a   Zhu, Wei ^b   Xu, Xiao ^b   Samuel, Edward T ^a   Monaghan, Melissa ^c   Zarrabi, Mohammad H ^a,d   Kim, Christi ^a   Dhundale, Anil ^c   Bahou, Wadie F ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Stony Brook University   (United States)

^c Long Island High Technology Incubator   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; JANUS KINASE 2;

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC MARKER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PHLEBOTOMY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; THROMBOCYTE; THROMBOCYTHEMIA; THROMBOCYTOSIS; AGED; BIOLOGICAL MODEL; CLASSIFICATION; COHORT ANALYSIS; DISCRIMINANT ANALYSIS; DNA MICROARRAY; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; SEXUAL DEVELOPMENT;

ADULT; AGED; COHORT STUDIES; DISCRIMINANT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENOTYPE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MODELS, GENETIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SEX CHARACTERISTICS; THROMBOCYTOSIS;

EID: 74949122650     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-224477     Document Type: Article

References (55)

1. Bahou WF. Genetic disorders of platelets. In: Kumar D, ed. Genomics and Clinical Medicine. Oxford, United Kingdom: Oxford University Press; 2006.
2. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood. 1997;89(6):1939-1943.
3. Moshfegh K, Wiullemin W, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet. 1999;353(9150):351-354.
4. Ouwehand WH. Platelet genomics and the risk of atherothrombosis. J Thromb Haemost. 2007;5[suppl 1]:188-195.
5. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006;367(9511):651-658.
6. Carlsson L, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2 beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood. 1999;93(11):3583-3586.
7. Carter A, Catto A, Bamford J, Grant P. Platelet GPIIIa PIA and GPIb variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol. 1998;18(7):1124-1131.
8. Baker RI, Eikelboom J, Lofthouse E, et al. Platelet glycoprotein Ibalpha Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood. 2001;98(1):36-40.
9. Frank MB, Reiner AP, Schwartz SM, et al. The Kozak sequence polymorphism of platelet glycoprotein Ibalpha and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood. 2001;97(4):875-879.
10. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood. 2003;101(6):2285-2293.
11. McRedmond JP, Park SD, Reilly DF, et al. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics. 2004;3(2):133-144.
12. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent prem-RNA splicing in anucleate platelets. Cell. 2005;122(3):379-391.
13. Weyrich A, Dixon D, Pabla R, et al. Signal-dependent translation of a regulatory protein, Bcl-2, in activated human platelets. Proc Nat Acad Sci U S A. 1998;95(10):5556-5561.
14. Rinder H, Schuster J, Rinder C, Wang C, Schwseidler H, Smith B. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood. 1998;91(4):1288-1294.
15. Schafer AI. Thrombocytosis. N Engl J Med. 2004;350(12):1211-1219.
16. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245(3):295-300.
17. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132-1136.
18. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45.
19. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
20. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
21. Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol. 2005;42(4):230-238.
22. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98(24):13790-13795.
23. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74.
24. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002;1(2):203-209.
25. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87.
26. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49-54.
27. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.
28. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34(1):29-39.
29. Mirza H, Yatsula V, Bahou WF. The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. Molecular characterization and evidence for functional coupling to the thrombin receptor. J Clin Invest. 1996;97(7):1705-1714.
30. Gnatenko DV, Cupit LD, Huang EC, Dhundale A, Perrotta PL, Bahou WF. Platelets express steroidogenic 17beta-hydroxysteroid dehydrogenases: distinct profiles predict the essential thrombocythemic phenotype. Thromb Haemost. 2005;94(2):412-421.
31. Schmidt VA, Chiariello CS, Capilla E, Miller F, Bahou WF. Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol. 2008;28(5):1489-1502.
32. Gnatenko DV, Perrotta PL, Bahou WF. Proteomic approaches to dissect platelet function: half the story. Blood. 2006;108(13):3983-3991.
33. Wang HY, Malek RL, Kwitek AE, et al. Assessing unmodified 70-mer oligonucleotide probe performance on glass-slide microarrays. Genome Biol. 2003;4:R5.
34. Wang E, Miller L, Ohnmacht G, Liu E, Marincola F. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol. 2000;18(4):457-459.
35. Cawley GC, Talbot NL. Fast exact leave-one-out cross-validation of sparse least-squares support vector machines. Neural Netw. 2004;17(10):1467-1475.
36. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
37. Beissbarth T, Speed TP. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics. 2004;20(9):1464-1465.
38. Schulze H, Shivdasani RA. Molecular mechanisms of megakaryocyte differentiation. Semin Thromb Hemost. 2004;30(4):389-398.
39. Antonioli E, Guglielmelli P, Poli G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93(1):41-48.
40. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29(4):365-371.
41. Schulze A, Downward J. Navigating gene expression using microarrays: a technology review. Nat Cell Biol. 2001;3(8):E190-E195.
42. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344(8):539-548.
43. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-1628.
44. Gnatenko D, Zhu W, Bahou WF. Multiplexed genetic profiling of human blood platelets using fluorescent microspheres. Thromb Haemost. 2008;100(5):929-936.
45. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol. 1995;23(9):996-1001.
46. Sakakura M, Wada H, Abe Y, et al. Usefulness of measurement of reticulated platelets for diagnosis of idiopathic thrombocytopenic purpura. Clin Appl Thromb Hemost. 2005;11(3):253-261.
47. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670.
48. Van Nostrand WE, Wagner SL, Suzuki M, et al. Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature. 1989;341(6242):546-549.
49. Xu F, Davis J, Miao J, et al. Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. Proc Natl Acad Sci U S A. 2005;102(50):18135-18140.
50. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
51. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature. 1975;253(5490):355-357.
52. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost. 1997;77(4):748-754.
53. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359(9302):189-198.
54. Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003;1(7):1343-1348.
55. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98(9):2720-2725.